Skip to content
Open access

Memory T Cells in MHC-Deficient Humanized Mice

Aug 2026 · bioRxiv · 0 citations · 53 references
Biology

TL;DR

This work investigated how elimination of murine MHC together with different conditioning regimens shapes human T-cell maturation in vivo, and revealed marked differences in T-cell differentiation across models.

Read PDF

Similar papers

Open access Sep 2026

Scalable expansion of human iNKT cells: single-cell profiling and in vivo control of GvHD with preserved GvL activity

Invariant natural killer T (iNKT) cells can limit graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation (HSCT), but their scarcity in peripheral blood limits therapeutic development. Current clinical-grade human iNKT expansion protocols mainly rely on IL-2, require prior iNKT-cell sorting, last...

Jordan Brouard, Cristina Caraiman, Ghislain Fievet et al. · 0 citations
Open access Aug 2026

Development of humanized mouse models for the preclinical evaluation of NK cell-based therapies

Introduction Novel immunotherapeutic strategies engaging human Natural Killer (huNK) cells have emerged as a promising treatment paradigm; however, their accurate preclinical evaluation requires reliable mouse models capable of supporting functional huNK cell engraftment. Methods We developed and characterized robust i...

Pauline Rettman, Samira Benhamouche-Trouillet, Georges Azar et al. · 0 citations
Review Open access Sep 2026

Stepwise Evolution of Immunodeficient Mouse Models: Focus on NCG Strains and Their Applications in Humanized Immune System Research

Immunodeficient and humanized mouse models have become essential tools for investigating human immunity, disease pathogenesis, and therapeutic evaluation. This review summarizes the stepwise evolution of these platforms, from nude and SCID mice to advanced NOD/SCID/Il2rgnull strains (NCG, NSG, or NOG), and highlights h...

Hong-Yan Sun, Jia-Lu Fan, Yu-Jing Zhang et al. · 0 citations
Sep 2026

Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.

Allogeneic CAR T cells could overcome limitations of autologous therapies but are limited by immune rejection. We evaluated 11 patients with large B‑cell lymphoma treated with a single lot of cemacabtagene ansegedleucel (cema-cel), an allogeneic anti‑CD19 CAR T product. Despite receiving identical infusion products, pa...

A. Jallouk, Zhong-Qi Ge, V. Kaimal et al. · 0 citations
Open access Sep 2026

CAR T cell-induced interferon gamma enhances MHC class I expression and sensitizes neuroblastoma to TCR-engineered T cell therapy

T cell receptor (TCR)-engineered T cells target antigens presented on major histocompatibility complex (MHC) class I molecules. MHC class I expression is often low in childhood tumors such as neuroblastoma but can be stimulated by interferon gamma (IFNγ). Chimeric antigen receptor (CAR) T cell effector function, in...

Alice Vitali, Jennie Padlo, Carlotta Caramel et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.